Over the course of this blog I’ve discussed how my goal was to deploy $2000 into the stock market. This typically took the form of one position, maybe two. However, in the past few days TD Ameritrade opted to eliminate its $6.95 trading fee. Schwab initially cut its trading fee to $0 to better compete with Robinhood. Other brokers, including … [Read more...]
3 Stocks for October 2019
With September coming to an end, I have to begin thinking of a new stock to buy in the month of October. Over the past several weeks we haven’t seen much movement in the broader market. We are still near all-time highs and overvalued stocks are everywhere. With the Fed cutting rates, a previously inverted yield curve, and ongoing trade tensions; … [Read more...]
Vaping Ban Batters Juul
I recently added Altria to my portfolio citing the transformation of its business and low valuation. Unfortunately, it turned out to be a falling knife, with the stock falling almost every day since I bought it. The concerns are threefold; high debt, declining cigarette sales, and a vaping ban. Over the past several months, there have been an … [Read more...]
Recent Buy: Altria
As I mentioned over the weekend, I bought two different stocks last month. My first purchase was drug company Abbvie (ABBV). In the previous post I outlined how Abbvie was a riskier company, but had numerous strengths and a strong dividend yield. My 2nd stock was none other than Altria (MO). Altria Group Inc. is the parent … [Read more...]
Recent Buy: ABBV
For the month of September, I went after a deep discount but took on some risk. I purchased 16 shares of Abbvie (ABBV) at a price of around $65/share. Abbvie is a global researcher, manufacturer, and marketer of pharmaceuticals. Products developed treat conditions related to autoimmune disorders, gastroenterology, neurology, oncology, … [Read more...]
Building Connections & Abolishing Fear
I recently made two additional stock purchases for the month of September. I’ll be going over these securities in subsequent posts. Needless to say, I found these two companies to be undervalued and unfairly punished by the market. I want to discuss this issue, where Wall Street punishes particular stocks for bad news, poor earnings numbers, and … [Read more...]